News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

Start News Corporate Information Other Corporate Information

Press releases

August 10, 2022

Egetis establishes subsidiary in the United States

July 13, 2022

Egetis receives positive opinion on orphan designation for Aladote® from the European Medicines Agency for the Prevention of Acute Liver Failure

June 20, 2022

Egetis appoints Sara Melton as President of North America

May 6, 2022

Egetis invites shareholders to an informal information meeting

May 5, 2022

Egetis initiates build-up of medical affairs and the commercial team with the appointment of three senior leaders

April 6, 2022

Egetis announces that the recruitment target has been met in the Emcitate® Triac Trial II study

March 24, 2022

Egetis receives positive EMA opinion for orphan designation of Emcitate for treatment of Resistance to Thyroid Hormone type beta (RTH-β)

March 14, 2022

Egetis announces participation at upcoming conferences

February 18, 2022

FDA grants Orphan Drug Designation to Emcitate® for treatment of Resistance to Thyroid Hormone type beta (RTH-β)

January 26, 2022

Egetis secures conditional acceptance for Emcitate® as brand name in the US

Share

Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10

E-mail: info@egetis.com